An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma.
Cho-Vega
Jeong Hee
JH
Department of Pathology, The Methodist Hospital, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Vega
Francisco
F
Medeiros
L Jeffrey
LJ